Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO... Read More

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1 ; Company believes results do not support a competitive benefit-risk profile for patients. CARGO to implement a workforce reduction of approximately 50%. Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.... Read More

71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 IND application for CRG-023, CARGO’s tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new... Read More

SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc . (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California. Gina Chapman, President and... Read More

57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1’25 with Phase 1 initiation planned for 2025 Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO... Read More

SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc . (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences. Jefferies London Healthcare Conference Gina Chapman, President and Chief Executive Officer, is... Read More

CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy First of its kind, tri-cistronic CAR T to express three independent CARs from a single vector, with each CAR having a distinct... Read More

All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) Completed $110 million private placement equity financing, extending cash runway through 2026 SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc . (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially... Read More

Ongoing Phase 1 study informed dose selection for CARGO’s currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) 1 , in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced disease Most... Read More

Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer... Read More

SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences. TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA Gina Chapman, President and Chief... Read More

Financing includes participation from new and existing investors Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 Extends cash runway through 2026 SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation,... Read More

26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications Ongoing follow-up from the Stanford Phase 1 study for firi-cel 1 to be presented at the 2024 European Hematology... Read More

SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company’s Board of Directors. Dr. Dhingra is a medical oncologist and a physician-scientist bringing more than 25 years of strategic... Read More

Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business... Read More

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44 th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, Massachusetts. Gina Chapman, President and Chief Executive... Read More

SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California. Gina Chapman, President and... Read More

SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported business updates and its financial results for the third quarter ended September 30, 2023. “This year has been transformational for our company. We experienced growth across our... Read More

SAN MATEO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO”), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the pricing of its initial public offering of 18,750,000 shares of its common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by... Read More